No evidence for relevant impact of renal replacement therapy on clinical effect of erythromycin in critically ill patients with sepsis
Main Authors: | Tom D. Y. Reijnders, Hessel Peters-Sengers, Tom van der Poll |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-02-01
|
Series: | Critical Care |
Online Access: | https://doi.org/10.1186/s13054-023-04359-z |
Similar Items
-
Effect of erythromycin on mortality and the host response in critically ill patients with sepsis: a target trial emulation
by: Tom D. Y. Reijnders, et al.
Published: (2022-05-01) -
Association between age and the host response in critically ill patients with sepsis
by: Erik H. A. Michels, et al.
Published: (2022-12-01) -
Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study
by: Peters-Sengers, H, et al.
Published: (2021) -
Robustness of sepsis-3 criteria in critically ill patients
by: Diana M. Verboom, et al.
Published: (2019-08-01) -
Continuous Renal Replacement Therapy and Mortality in Critically Ill Obese Adults
by: Bradley J. Peters, PharmD, et al.
Published: (2023-11-01)